Quintrio
Home

Stock overview

Tiziana Life Sciences Ltd. Common Shares

TLSA

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Last trade $0.6765
Day change +$0.1003 (+17.41%)
Day range $0.574 – $0.709
Volume 562,187
Market cap $74M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for TLSA.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for TLSA.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Tiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary Progressive Multiple Sclerosis Treated with Intranasal Foralumab

Tiziana Life Sciences announced positive topline results from its Phase 2a INFORM-MS trial of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for treating non-active secondary progressive multiple sclerosis (na-SPMS). The 50 μg dose met the primary endpoint with statistically significant reduction in microglial activation on TSPO PET imaging (p=0.0168) and showed clinically meaningful improvements in fatigue scores. Results were consistent with longer-term data from an expanded access program treating up to 14 patients for up to three years, with favorable safety profile and no anti-drug antibodies detected.

GlobeNewswire Inc.

Tiziana to Host Investor Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline Results

Tiziana Life Sciences announced positive Phase 2a results from its INFORM-MS trial of intranasal foralumab for non-active secondary progressive multiple sclerosis (na-SPMS). The trial met its primary endpoint with statistically significant reduction in microglial activation (p=0.0168) at the 50μg dose and showed clinically meaningful fatigue improvements in both dose arms after 12 weeks. The company will host an investor call with key opinion leaders on November 9, 2026, to discuss the results and plans to engage with the FDA regarding next steps.

GlobeNewswire Inc.

Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial

Tiziana Life Sciences announced completion of patient enrollment in its Phase 2a randomized, double-blind, placebo-controlled trial (INFORM-MS) evaluating intranasal foralumab in 48 patients with non-active Secondary Progressive Multiple Sclerosis. Topline data is expected in late Q3 2026 and will be presented at the ACTRIMS/ECTRIMS meeting in October 2026. The trial includes a six-month open-label extension phase to assess long-term safety and sustained benefit.

GlobeNewswire Inc.

Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function

Tiziana Life Sciences announced positive preclinical data published on bioRxiv showing that intranasal foralumab, an anti-CD3 monoclonal antibody, significantly reduces neuroinflammation and improves cognitive function in a Long COVID mouse model. The study, conducted by researchers from Yale University and Harvard Medical School, demonstrated that the treatment increases regulatory T cells in the brain, restores neurogenesis, and rescues cognitive deficits. The company is advancing foralumab through clinical trials for multiple neurological conditions including multiple sclerosis, Alzheimer's disease, and ALS.

Benzinga

Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares

Tiziana Life Sciences (NASDAQ: TLSA) closed an oversubscribed $8.8 million registered direct offering of 7.04 million ordinary shares at $1.25 per share, with warrants providing up to $10.56 million in additional potential proceeds. The offering was led by CEO Ivor Elrifi and Executive Chairman Gabriele Cerrone. Proceeds will fund Phase 2 clinical trials for intranasal foralumab in na-SPMS and MSA patients.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Oct 29, 20192-for-1forward split